Open access
Open access
Powered by Google Translator Translator

SGLT2 inhibitor reduces the risk of hyperkalemia in patients with heart failure.

13 Jun, 2022 | 07:52h | UTC

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled – European Heart Journal

Editorial: Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure

Related: Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal


Commentary on Twitter

Under a license


Stay Updated in Your Specialty

No spam, just news.